Business
Iovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients in the Lifileucel Metastatic Melanoma Study who are Primary Refractory to Anti-PD-1/L1 Therapy
- 41 percent objective response rate (ORR) as assessed by the investigator in 42 patients who were primary refractory to anti-PD-1/L1 therapy - - Median
About this update from Iovance Biotherapeutics, Inc.
[{"type":"text","content":"- 41 percent objective response rate (ORR) as assessed by the investigator in 42 patients who were primary refractory to anti-PD-1/L1 therapy - - Median duration of response (DOR) was not reached as assessed by investigator at 12 months of study follow-up for the primary refractory subgroup - \n SAN CARLOS, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced results of a subgroup analysis of Cohort 2 of the Phase 2 lifileucel metastatic melanoma study C-144-01 in patients who were primary refractory to prior anti-PD-1/L1 therapy. An abstract with details of the analysis was accepted as a late-breaking poster at the 16th International Congress of the Society for Melanoma Research (SMR) being held Nov. 20-22 in Salt Lake City. Highlights from the poster, presented by study investigator Omid Hamid, M.D., Chief of Translational Research and Immunotherapy and Director of Melanoma Therapeutics at the Angeles Clinic and Research Institute of Los Angeles, on Thursday, Nov. 21, 2019, include: In 42 primary refractory patients enrolled in Cohort 2 of C-144-01 study, defined as having had the best response of progressive disease (PD) on their first anti-PD-1/L1 treatment, an objective response rate (ORR) of 41 percent, as assessed by the investigator, was observedMedian duration of response (DOR) was not reached at 12 months of study follow-up (range: 2.8+ to 21.2+ months)71 percent of responders who are primary refractory to anti PD-1/L1 therapy remain on study “Patients who are primary refractory to prior anti-PD-1/L1 therapy have very limited therapeutic options and yet form a large population of diagnosed metastatic melanoma patients,” commented Maria Fardis, Ph.D., MBA, president and chief executive officer of Iovance. “Tumor infiltrating lymphocyte (TIL) therapy developed by Iovance has shown strong efficacy for patients with relapsed or refractory metastatic melanoma. In the subgroup analysis conducted for primary refractory patients in our Cohort 2 of the C-144-01 study, TIL demonstrates excellent efficacy and durability of response thus far. We are very pleased to see that the Iovance TIL may offer a therapeutic option for this patient population.” Cohort 2 in the ongoing C-144-01 study inclu...